-
1
-
-
0003964363
-
-
American-Cancer-Society. Atlanta: American Cancer Society
-
American-Cancer-Society. Cancer Facts & Figures, vol. 2012 Atlanta: American Cancer Society, 2012.
-
(2012)
Cancer Facts & Figures
, vol.2012
-
-
-
2
-
-
84890560863
-
-
Canadian-Cancer-Society. Toronto, ON: Canadian Cancer Society
-
Canadian-Cancer-Society. Canadian Cancer Statistics, vol. 2012 Toronto, ON: Canadian Cancer Society, 2012.
-
(2012)
Canadian Cancer Statistics
, vol.2012
-
-
-
3
-
-
0028228254
-
Transient increase in the risk of breast cancer after giving birth
-
Lambe M, Hsieh C, Trichopoulos D, et al. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994; 331: 5-9.
-
(1994)
N Engl J Med
, vol.331
, pp. 5-9
-
-
Lambe, M.1
Hsieh, C.2
Trichopoulos, D.3
-
4
-
-
28944446431
-
The many faces of PPARγamma
-
Lehrke M, Lazar MA,. The many faces of PPARγamma. Cell 2005; 123: 993-9.
-
(2005)
Cell
, vol.123
, pp. 993-999
-
-
Lehrke, M.1
Lazar, M.A.2
-
6
-
-
34547603895
-
PPARs and molecular mechanisms of transrepression
-
Ricote M, Glass CK,. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007; 1771: 926-35.
-
(2007)
Biochim Biophys Acta
, vol.1771
, pp. 926-935
-
-
Ricote, M.1
Glass, C.K.2
-
7
-
-
0031898610
-
PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
-
Spiegelman BM,. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
-
(1998)
Diabetes
, vol.47
, pp. 507-514
-
-
Spiegelman, B.M.1
-
8
-
-
0034861516
-
A review of rosiglitazone in type 2 diabetes mellitus
-
Werner AL, Travaglini MT,. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-99.
-
(2001)
Pharmacotherapy
, vol.21
, pp. 1082-1099
-
-
Werner, A.L.1
Travaglini, M.T.2
-
9
-
-
0030047806
-
Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
-
Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-66.
-
(1996)
Endocrinology
, vol.137
, pp. 354-366
-
-
Braissant, O.1
Foufelle, F.2
Scotto, C.3
-
10
-
-
0031830264
-
Differential expression of the peroxisome proliferator-activated receptor gamma (PPARγamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse
-
Jain S, Pulikuri S, Zhu Y, et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARγamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998; 153: 349-54.
-
(1998)
Am J Pathol
, vol.153
, pp. 349-354
-
-
Jain, S.1
Pulikuri, S.2
Zhu, Y.3
-
11
-
-
0031993322
-
Terminal differentiation of human breast cancer through PPAR gamma
-
Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
-
(1998)
Mol Cell
, vol.1
, pp. 465-470
-
-
Mueller, E.1
Sarraf, P.2
Tontonoz, P.3
-
12
-
-
0032555196
-
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
-
Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95: 8806-11.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 8806-8811
-
-
Elstner, E.1
Muller, C.2
Koshizuka, K.3
-
13
-
-
47349108152
-
Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARγamma) ligand
-
Yu HN, Lee YR, Noh EM, et al. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARγamma) ligand. Cell Biol Int 2008; 32: 906-12.
-
(2008)
Cell Biol Int
, vol.32
, pp. 906-912
-
-
Yu, H.N.1
Lee, Y.R.2
Noh, E.M.3
-
14
-
-
0033571433
-
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis
-
Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 5671-3.
-
(1999)
Cancer Res
, vol.59
, pp. 5671-5673
-
-
Suh, N.1
Wang, Y.2
Williams, C.R.3
-
15
-
-
0035002199
-
Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands
-
Pighetti GM, Novosad W, Nicholson C, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 2001; 21: 825-9.
-
(2001)
Anticancer Res
, vol.21
, pp. 825-829
-
-
Pighetti, G.M.1
Novosad, W.2
Nicholson, C.3
-
16
-
-
4143150044
-
PPARγamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
-
Nicol CJ, Yoon M, Ward JM, et al. PPARγamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004; 25: 1747-55.
-
(2004)
Carcinogenesis
, vol.25
, pp. 1747-1755
-
-
Nicol, C.J.1
Yoon, M.2
Ward, J.M.3
-
17
-
-
58349086542
-
Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification
-
Yin Y, Yuan H, Zeng X, et al. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res 2009; 69: 687-94.
-
(2009)
Cancer Res
, vol.69
, pp. 687-694
-
-
Yin, Y.1
Yuan, H.2
Zeng, X.3
-
18
-
-
84865171803
-
Stromal adipocyte PPARγamma protects against breast tumorigenesis
-
Skelhorne-Gross G, Reid AL, Apostoli AJ, et al. Stromal adipocyte PPARγamma protects against breast tumorigenesis. Carcinogenesis 2012; 33: 1412-20.
-
(2012)
Carcinogenesis
, vol.33
, pp. 1412-1420
-
-
Skelhorne-Gross, G.1
Reid, A.L.2
Apostoli, A.J.3
-
20
-
-
10044251948
-
Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland
-
Morroni M, Giordano A, Zingaretti MC, et al. Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A 2004; 101: 16801-6.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 16801-16806
-
-
Morroni, M.1
Giordano, A.2
Zingaretti, M.C.3
-
21
-
-
0035851187
-
PPARγamma: A nuclear regulator of metabolism, differentiation, and cell growth
-
Rosen ED, Spiegelman BM,. PPARγamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
-
(2001)
J Biol Chem
, vol.276
, pp. 37731-37734
-
-
Rosen, E.D.1
Spiegelman, B.M.2
-
22
-
-
0030658840
-
Cre-mediated gene deletion in the mammary gland
-
Wagner KU, Wall RJ, St-Onge L, et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997; 25: 4323-30.
-
(1997)
Nucleic Acids Res
, vol.25
, pp. 4323-4330
-
-
Wagner, K.U.1
Wall, R.J.2
St-Onge, L.3
-
23
-
-
84862630475
-
NetWalker: A contextual network analysis tool for functional genomics
-
Komurov K, Dursun S, Erdin S, et al. NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 2012; 13: 282.
-
(2012)
BMC Genomics
, vol.13
, pp. 282
-
-
Komurov, K.1
Dursun, S.2
Erdin, S.3
-
24
-
-
0037124098
-
Loss of the peroxisome proliferation-activated receptor gamma (PPARγamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility
-
Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARγamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002; 277: 17830-5.
-
(2002)
J Biol Chem
, vol.277
, pp. 17830-17835
-
-
Cui, Y.1
Miyoshi, K.2
Claudio, E.3
-
25
-
-
0036205326
-
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
-
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Jr., Gonzalez FJ,. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002; 22: 2607-19.
-
(2002)
Mol Cell Biol
, vol.22
, pp. 2607-2619
-
-
Akiyama, T.E.1
Sakai, S.2
Lambert, G.3
Nicol, C.J.4
Matsusue, K.5
Pimprale, S.6
Lee, Y.H.7
Ricote, M.8
Glass, C.K.9
Brewer Jr., H.10
Gonzalez, F.J.11
-
26
-
-
0141446024
-
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
-
Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003; 278: 34268-76.
-
(2003)
J Biol Chem
, vol.278
, pp. 34268-34276
-
-
Gavrilova, O.1
Haluzik, M.2
Matsusue, K.3
-
27
-
-
17044430286
-
PPARγamma in endothelial cells influences high fat diet-induced hypertension
-
Nicol CJ, Adachi M, Akiyama TE, et al. PPARγamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005; 18: 549-56.
-
(2005)
Am J Hypertens
, vol.18
, pp. 549-556
-
-
Nicol, C.J.1
Adachi, M.2
Akiyama, T.E.3
-
28
-
-
33747177047
-
Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes
-
Rosak C, Standl E, Reblin T, et al. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract 2006; 60: 1040-7.
-
(2006)
Int J Clin Pract
, vol.60
, pp. 1040-1047
-
-
Rosak, C.1
Standl, E.2
Reblin, T.3
-
29
-
-
33748748206
-
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
-
Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
-
(2006)
Lancet
, vol.368
, pp. 1096-1105
-
-
Gerstein, H.C.1
Yusuf, S.2
Bosch, J.3
-
30
-
-
34547618810
-
Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk
-
Wan Y, Saghatelian A, Chong LW, et al. Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev 2007; 21: 1895-908.
-
(2007)
Genes Dev
, vol.21
, pp. 1895-1908
-
-
Wan, Y.1
Saghatelian, A.2
Chong, L.W.3
-
31
-
-
78349256721
-
The role of the microenvironment in mammary gland development and cancer
-
Polyak K, Kalluri R,. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010; 2: a003244.
-
(2010)
Cold Spring Harb Perspect Biol
, vol.2
-
-
Polyak, K.1
Kalluri, R.2
-
32
-
-
84864925226
-
The key to unlocking the chemotherapeutic potential of PPARγamma ligands: Having the right combination
-
Skelhorne-Gross G, Nicol CJ,. The key to unlocking the chemotherapeutic potential of PPARγamma ligands: having the right combination. PPAR Res 2012; 2012: 946943.
-
(2012)
PPAR Res
, vol.2012
, pp. 946943
-
-
Skelhorne-Gross, G.1
Nicol, C.J.2
-
33
-
-
74949111637
-
Targeting CCL11 in the treatment of ovarian cancer
-
Nolen BM, Lokshin AE,. Targeting CCL11 in the treatment of ovarian cancer. Exp Opin Ther Tar 2010; 14: 157-67.
-
(2010)
Exp Opin Ther Tar
, vol.14
, pp. 157-167
-
-
Nolen, B.M.1
Lokshin, A.E.2
-
34
-
-
84878802497
-
CCL5 as a potential immunotherapeutic target in triple-negative breast cancer
-
Lv D, Zhang Y, Kim HJ, Zhang L, Ma X,. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cellular & molecular immunology 2013; 10: 303-10.
-
(2013)
Cellular & Molecular Immunology
, vol.10
, pp. 303-310
-
-
Lv, D.1
Zhang, Y.2
Kim, H.J.3
Zhang, L.4
Ma, X.5
-
35
-
-
84883890972
-
Oxidative stress and lipid peroxidation products in cancer progression and therapy
-
Barrera G,. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012; 2012: 137289.
-
(2012)
ISRN Oncol
, vol.2012
, pp. 137289
-
-
Barrera, G.1
-
36
-
-
15444371092
-
Nicotine inactivation of the proapoptotic function of Bax through phosphorylation
-
Xin M, Deng X,. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005; 280: 10781-9.
-
(2005)
J Biol Chem
, vol.280
, pp. 10781-10789
-
-
Xin, M.1
Deng, X.2
-
37
-
-
0035873953
-
Tumor suppressor and anti-inflammatory actions of PPARγamma agonists are mediated via upregulation of PTEN
-
Patel L, Pass I, Coxon P, et al. Tumor suppressor and anti-inflammatory actions of PPARγamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11: 764-8.
-
(2001)
Curr Biol
, vol.11
, pp. 764-768
-
-
Patel, L.1
Pass, I.2
Coxon, P.3
-
38
-
-
75649133232
-
Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγamma and inhibition of ERK 1/2
-
Moon HS, Guo DD, Lee HG, et al. Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγamma and inhibition of ERK 1/2. Cancer Sci 2010; 101: 396-402.
-
(2010)
Cancer Sci
, vol.101
, pp. 396-402
-
-
Moon, H.S.1
Guo, D.D.2
Lee, H.G.3
-
39
-
-
0036714806
-
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
-
Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-70.
-
(2002)
Development
, vol.129
, pp. 4159-4170
-
-
Li, G.1
Robinson, G.W.2
Lesche, R.3
-
40
-
-
0033152120
-
Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo
-
Schorr K, Li M, Bar-Peled U, et al. Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo. Cancer Res 1999; 59: 2541-5.
-
(1999)
Cancer Res
, vol.59
, pp. 2541-2545
-
-
Schorr, K.1
Li, M.2
Bar-Peled, U.3
-
41
-
-
0033577766
-
Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage
-
Shibata MA, Liu ML, Knudson MC, et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999; 18: 2692-701.
-
(1999)
EMBO J
, vol.18
, pp. 2692-2701
-
-
Shibata, M.A.1
Liu, M.L.2
Knudson, M.C.3
-
42
-
-
67649220699
-
Mammary involution and breast cancer risk: Transgenic models and clinical studies
-
Radisky DC, Hartmann LC,. Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia 2009; 14: 181-91.
-
(2009)
J Mammary Gland Biol Neoplasia
, vol.14
, pp. 181-191
-
-
Radisky, D.C.1
Hartmann, L.C.2
-
43
-
-
0037089506
-
Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer
-
Kundu N, Fulton AM,. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002; 62: 2343-6.
-
(2002)
Cancer Res
, vol.62
, pp. 2343-2346
-
-
Kundu, N.1
Fulton, A.M.2
-
44
-
-
79952706985
-
Transforming growth factor-beta and the hallmarks of cancer
-
Tian M, Neil JR, Schiemann WP,. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951-62.
-
(2011)
Cell Signal
, vol.23
, pp. 951-962
-
-
Tian, M.1
Neil, J.R.2
Schiemann, W.P.3
-
45
-
-
82955212867
-
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin
-
Holmes MD, Chen WY, Schnitt SJ, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 2011; 130: 657-62.
-
(2011)
Breast Cancer Res Treat
, vol.130
, pp. 657-662
-
-
Holmes, M.D.1
Chen, W.Y.2
Schnitt, S.J.3
-
46
-
-
33746906228
-
Immune enhancement and anti-tumour activity of IL-23
-
Hao JS, Shan BE,. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother CII 2006; 55: 1426-31.
-
(2006)
Cancer Immunol Immunother CII
, vol.55
, pp. 1426-1431
-
-
Hao, J.S.1
Shan, B.E.2
-
47
-
-
0035052916
-
Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1
-
Wang C, Fu M, D'Amico M, et al. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 2001; 21: 3057-70.
-
(2001)
Mol Cell Biol
, vol.21
, pp. 3057-3070
-
-
Wang, C.1
Fu, M.2
D'Amico, M.3
|